View in EDS HTML Full Text PDF Full Text

A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".

Saved in:
Bibliographic Details
Title: A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".
Authors: Ständer S; Section Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany., Pinter A; Goethe-University Frankfurt Am Main, Frankfurt Am Main, Germany., Hougeir FG; Southeast Research Specialists, Douglasville, GA, USA., Guyot P; Sanofi, Gentilly, France., Xu Y; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Praestgaard AH; Sanofi, Cambridge, MA, USA., Freemantle N; Institute of Clinical Trials and Methodology, University College London, London, UK., Rossi AB; Sanofi, Cambridge, MA, USA., Bégo-Le-Bagousse G; Sanofi, Gentilly, France., Wang Z; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Noonan K; Sanofi, Cambridge, MA, USA., Bastian M; Sanofi, Frankfurt, Germany. mike.bastian@sanofi.com.
Source: Dermatology and therapy [Dermatol Ther (Heidelb)] 2026 Feb; Vol. 16 (2), pp. 1433-1437. Date of Electronic Publication: 2025 Dec 29.
Publication Type: Letter
Journal Info: Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41460564
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ständer+S%22">Ständer S</searchLink>; Section Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Pinter+A%22">Pinter A</searchLink>; Goethe-University Frankfurt Am Main, Frankfurt Am Main, Germany.<br /><searchLink fieldCode="AU" term="%22Hougeir+FG%22">Hougeir FG</searchLink>; Southeast Research Specialists, Douglasville, GA, USA.<br /><searchLink fieldCode="AU" term="%22Guyot+P%22">Guyot P</searchLink>; Sanofi, Gentilly, France.<br /><searchLink fieldCode="AU" term="%22Xu+Y%22">Xu Y</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Praestgaard+AH%22">Praestgaard AH</searchLink>; Sanofi, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Freemantle+N%22">Freemantle N</searchLink>; Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Rossi+AB%22">Rossi AB</searchLink>; Sanofi, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bégo-Le-Bagousse+G%22">Bégo-Le-Bagousse G</searchLink>; Sanofi, Gentilly, France.<br /><searchLink fieldCode="AU" term="%22Wang+Z%22">Wang Z</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Noonan+K%22">Noonan K</searchLink>; Sanofi, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bastian+M%22">Bastian M</searchLink>; Sanofi, Frankfurt, Germany. mike.bastian@sanofi.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101590450%22">Dermatology and therapy</searchLink> [Dermatol Ther (Heidelb)] 2026 Feb; Vol. 16 (2), pp. 1433-1437. <i>Date of Electronic Publication: </i>2025 Dec 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Healthcare+Communications%22">Springer Healthcare Communications </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101590450 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2193-8210 (Print) <i>NLM ISO Abbreviation: </i>Dermatol Ther (Heidelb) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41460564
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s13555-025-01627-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1433
    Titles:
      – TitleFull: A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ständer S
      – PersonEntity:
          Name:
            NameFull: Pinter A
      – PersonEntity:
          Name:
            NameFull: Hougeir FG
      – PersonEntity:
          Name:
            NameFull: Guyot P
      – PersonEntity:
          Name:
            NameFull: Xu Y
      – PersonEntity:
          Name:
            NameFull: Praestgaard AH
      – PersonEntity:
          Name:
            NameFull: Freemantle N
      – PersonEntity:
          Name:
            NameFull: Rossi AB
      – PersonEntity:
          Name:
            NameFull: Bégo-Le-Bagousse G
      – PersonEntity:
          Name:
            NameFull: Wang Z
      – PersonEntity:
          Name:
            NameFull: Noonan K
      – PersonEntity:
          Name:
            NameFull: Bastian M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2026 Feb
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2193-8210
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Dermatology and therapy
              Type: main
ResultId 1